Travere Therapeutics gains FDA approval for sparsentan in FSGS
In the Phase III DUPLEX Study, Filspari reduced proteinuria by 46% and irbesartan by 30% over 108 weeks.
Drug Development
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
EverSea Medicines to acquire Hasten Biopharmaceuticals
Jeito Capital secures over $1.2bn for new biopharma investments
RoosterBio and MineBio team up to expand MSC solutions access in China
